Loncastuximab Tesirine and Epcoritamab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aggressive Diffuse Large B-cell Lymphoma
Conditions
Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B
Trial Timeline
Oct 15, 2025 → Jan 15, 2030
NCT ID
NCT07197307About Loncastuximab Tesirine and Epcoritamab
Loncastuximab Tesirine and Epcoritamab is a phase 2 stage product being developed by AbbVie for Aggressive Diffuse Large B-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07197307. Target conditions include Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3B.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07197307 | Phase 2 | Recruiting |
Competing Products
11 competing products in Aggressive Diffuse Large B-cell Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy | Johnson & Johnson | Phase 2 | 52 |
| Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib | AstraZeneca | Phase 2 | 52 |
| Midostaurin | Novartis | Phase 2 | 52 |
| Imatinib | Novartis | Phase 2 | 52 |
| Bendamustine and subcutaneous rituximab | Roche | Phase 2 | 52 |
| Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Bristol Myers Squibb | Phase 1/2 | 40 |
| Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Bristol Myers Squibb | Phase 2 | 51 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| cemiplimab + odronextamab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Zanzalintinib | Exelixis | Phase 2 | 49 |
| PRT2527 + Zanubrutinib + Venetoclax | Prelude Therapeutics | Phase 1 | 25 |